Publications


2021   |   2020   |   2019   |   2018   |   2017   |   2016   |   2015   |   2014   |   2013   |   2012   |   2011   |   2010   |   2009   |   2008   |   2007   |   2006   |   2005   |   2004   |   2003   |   2002   |   2001   |   2000   |  

2021

Monitoring eIF4E-Dependent Nuclear 3' End mRNA Cleavage
Mildred Delaleau Methods Mol Biol. (2021) 2209:347-361

2020

The eukaryotic translation initiation factor eIF4E elevates steady-state m(7)G capping of coding and noncoding transcripts.
Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV, Gasiorek J, Cowling VH, Cerchietti L, Borden KLB. Proc Natl Acad Sci U S A. (2020) 117(43):26773-26783

The Nuclear Pore Complex and mRNA Export in Cancer.
Borden KLB. Cancers (Basel). (2020) 13(1):42

The Diversity, Plasticity, and Adaptability of Cap-Dependent Translation Initiation and Its Associated Machinery
Borden KLB, Volpon L. RNA Biol. (2020) 17(9):1239-1251

2019

Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.
Coutinho de Oliveira L, Volpon L, Rahardjo AK, Osborne MJ, Culjkovic-Kraljacic B, Trahan C, Oeffinger M, Kwok BH, Borden KLB. Proc Natl Acad Sci U S A. (2019) 116(48):24056-24065

Nuclear eIF4E Stimulates 3'-End Cleavage of Target RNAs.
Davis MR, Delaleau M, Borden KLB. Cell Rep. (2019) 27(5):1397-1408

Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E.
Volpon L, Osborne MJ, Borden KLB. Curr Protein Pept Sci. (2019) 20(6):525-535

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA. Oncogene. (2019) 38(13):2241-2262

Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y.
Coutinho de Oliveira L, Volpon L, Osborne MJ, Borden KLB. Biomol NMR Assign. (2019) 13(1):9-13

Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.
Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden KLB. J Mol Biol. (2019) 431(2):258-272

GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.
Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB. ACS Chem Biol. (2019) 14(3):348-355

CDK9 and mTOR: trading places.
Borden KLB. Blood. (2019) 133(11):1167-1168

2018

The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.
Culjkovic-Kraljacic B, Borden KLB. Front Genet. (2018) 9:512

Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ, Coutinho de Oliveira L, Volpon L, Borden KLB. Biomol NMR Assign. (2018) 12(2):315-318

A TFEB nuclear export signal integrates amino acid supply and glucose availability.
Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden KLB, Filippakopoulos P, Goding CR. Nat Commun. (2018) 9(1):2685

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden KLB, Patton EE, Goding CR. Proc Natl Acad Sci USA. (2018) 115(37):E8668-E8677

mRNA Export and Its Dysregulation in Disease.
Culjkovic-Kraljacic B, Borden KLB. Nuclear-Cytoplasmic Transport (Chapter 8) in the book series “Nucleic Acids and Molecular Biology”, edited by Weidong Yang, Springer Publishers.

2017

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.
Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden KL. Elife. (2017) 6. pii: e29830

A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.
Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB. RNA. (2017) 23(6):927-937

2016

The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.
Borden KL. Translation (Austin) (2016) 4(2):e1220899

Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden KL. Proc Natl Acad Sci U S A. (2016) 113(19):5263-5268

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden KL, Cerchietti L. Blood (2016) 127(7):858-868

2015

Sonic Hedgehog factor Gli1: As good as resistant.
Zahreddine HA, Culjkovic-Kraljacic B, Borden KL. Mol Cell Oncol. (2015) 2(1):e961827

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ, Borden KL. Immunol Rev. (2015) 263(1):210-223

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL. Haematologica. (2015) 100(1):e7-9

Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.
Zahreddine HA, Borden KL. Clin Cancer Res. (2015) 21(10):2207-2210

Multiple Export Mechanisms for mRNAs.
Delaleau M, Borden KL. Cells. (2015) 4(3):452-473

2014

When will resistance be futile?
Borden KL.Cancer Res. (2014) 74(24):7175-7180

MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.
Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB. Nat Commun. (2014) 5:5413

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. Nature. (2014) 511(7507):90-93
Featured in Nature Reviews Cancer, La Presse, Radio Canada, ScienceDaily.com, Sciences Newsline Medicine, ChemFeeds, World Pharma News, Chemical Research in Toxicology, Sci-Business Exchange.

LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.
Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KLB, Rauscher FJ 3rd Cancer Res. (2014) 74(5):1390-1403

TIF-90 tips the balance in rRNA synthesis.
Borden KL Blood. (2014) 124(4):467-468

Inducible drug modification: a new form of resistance.
Culjkovic-Kraljacic B, Zahreddine HA, Borden KL. Cell Cycle. (2014) 13(16):2485-2486

2013

eIF4E3, a new actor in mRNA metabolism and tumor suppression.
Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KL.Cell Cycle. (2013) 12(8):1159-1160

Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL. Biochem Biophys Res Commun. (2013) 434(3):614-619

The oncogene eIF4E: using biochemical insights to target cancer.
Carroll M, Borden KL. J Interferon Cytokine Res. (2013) 33(5):227-238

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.
Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden KL. Leukemia. (2013) 27(10):2047-2055

eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.
Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden KL. Proc Natl Acad Sci U S A. (2013) 110(10):3877-3882

RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden KL, Meloche S, Roux PP. Oncogene. (2013) 32(24):2917-2926

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L. Cancer Discov. (2013) 3(9):1002-1019

Aiding and abetting cancer: mRNA export and the nuclear pore.
Culjkovic-Kraljacic B, Borden KL. Trends Cell Biol. (2013) 23(7):328-335

Mechanisms and insights into drug resistance in cancer.
Zahreddine H, Borden KL. Front Pharmacol. (2013) 4:28

2012

The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.
Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL.Cell Rep. (2012) 2(2):207-215

Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E.
Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, Park HW, Borden KL. J Mol Biol. (2012) 415(5):781-792

mRNA export and cancer.
Siddiqui N, Borden KL. Wiley Interdiscip Rev RNA. (2012) 3(1):13-25

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A. Cancer Cell. (2012) 22(6):812-824 (Faculty of 1000 rated)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).
Assouline S, Cocolakis E, Borden KL. Cancers (Basel). (2012) 4(4):1161-1179

The PML protein.
Culjkovic-Kraljacic, B and Borden, KLB. McGraw Hill Yearbook of Science and Technology. (2012) Pages 197-199

2011

Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.
Borden KL. Clin Invest Med. (2011) 34(6):E315

Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Kraljacic BC, Arguello M, Amri A, Cormack G, Borden KL. Leukemia. (2011) 25(7):1197-1200

Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH Jr. Clin Cancer Res. (2011) 17(9):2874-2884

Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway.
Déléris P1, Trost M, Topisirovic I, Tanguay PL, Borden KL, Thibault P, Meloche S. J Biol Chem. (2011) 286(8):6470-6478 (Faculty of 1000 rated)

2010

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL, Culjkovic-Kraljacic B. Leuk Lymphoma. (2010) 51(10):1805-1815

Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E.
Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL. Proc Natl Acad Sci U S A. (2010) 107(12):5441-5446

An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein.
Garcia CC, Topisirovic I, Djavani M, Borden KL, Damonte EB, Salvato MS. Biochem Biophys Res Commun. (2010) 393(4):625-630

eIF4E (eukaryotic translation initiation factor 4E)
Borden KLB, Culjkovic-Kraljacic B, Volpon L Atlas Genet Cytogenet Oncol Haematol. (2010)

Cell biology. Puzzled by PML.
Culjkovic-Kraljacic B, Borden KL. Science. (2010) 330(6008):1183-1184

2009

Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.
Culjkovic B, Borden KL. J Oncol. (2009) 2009:981679

A mechanism of nucleocytoplasmic trafficking for the homeodomain protein PRH.
Ploski JE, Topisirovic I, Park KW, Borden KL, Radu A. Mol Cell Biochem. (2009) 332(1-2):173-181

Tissue targeting in cancer: eIF4E's tale.
Borden KL. Clin Cancer Res. (2009) 15(13):4254-4255

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr, Borden KL. Blood. (2009) 114(2):257-260
Featured in CTV National News, Globe and Mail, Le Devoir, CBC Radio Quebec , Radio Canada, Genetic Engineering & Biotech News; CIHR annual report

The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes.
Topisirovic I, Siddiqui N, Borden KL. Cell Cycle. (2009) 8(7):960-961

Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP.
Topisirovic I, Siddiqui N, Lapointe VL, Trost M, Thibault P, Bangeranye C, Piñol-Roma S, Borden KL. EMBO J. (2009) 28(8):1087-1098 (Faculty of 1000 Top 10 Hidden Jewels)

Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer.
Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T, Borden KL. Mol Cell Biol. (2009) 29(5):1152-1162

Control of p53 multimerization by Ubc13 is JNK-regulated.
Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA. Proc Natl Acad Sci USA. (2009) 106(31):12676-12681

Two fundamentally distinct PCNA interaction peptides contribute to chromatin assembly factor 1 function.
Rolef Ben-Shahar T, Castillo AG, Osborne MJ, Borden KL, Kornblatt J, Verreault A. Mol Cell Biol. (2009) 29(24):6353-6365

2008

NMR assignment of the arenaviral protein Z from Lassa fever virus.
Volpon L, Osborne MJ, Borden KL. Biomol NMR Assign. (2008) 2(1):81-84

Ribavirin targets eIF4E dependent Akt survival signaling.
Tan K, Culjkovic B, Amri A, Borden KL. Biochem Biophys Res Commun. (2008) 375(3):341-345

Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?
Borden KL. Biochim Biophys Acta. (2008) 1783(11):2145-2154

The eIF4E RNA regulon promotes the Akt signaling pathway.
Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. J Cell Biol. (2008) 181(1):51-63

2007

Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E.
Culjkovic B, Topisirovic I, Borden KL. Cell Cycle. (2007) 6(1):65-69

2006

eIF4E is a central node of an RNA regulon that governs cellular proliferation.
Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. J Cell Biol. (2006) 175(3):415-426

Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands.
Volpon L, Osborne MJ, Topisirovic I, Siddiqui N, Borden KL. EMBO J. (2006) 25(21):5138-5149

NMR assignment of human eukaryotic translation initiation factor 4E (eIF4E) in its cap-free form.
Volpon L, Osborne MJ, Borden KL. J Biomol NMR. (2006) 36 Suppl 1:65

2005

Further evidence that ribavirin interacts with eIF4E.
Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, Borden KL. RNA. (2005) 11(12):1762-1766

Homeodomain proteins and eukaryotic translation initiation factor 4E (eIF4E): an unexpected relationship.
Topisirovic I, Borden KL. Histol Histopathol. (2005) 20(4):1275-1284

eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR.
Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. J Cell Biol. (2005) 169(2):245-256

Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.
Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Mol Cell Biol. (2005) 25(3):1100-1112

2004

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Proc Natl Acad Sci U S A. (2004) 101(52):18105-18110

Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.
Topisirovic I, Ruiz-Gutierrez M, Borden KL. Cancer Res. (2004) 64(23):8639-8642

2003

Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis.
Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Mol Cell Biol. (2003) 23(24):8992-9002

The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth.
Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. EMBO J. (2003) 22(3):689-703

2002

Control of biochemical reactions through supramolecular RING domain self-assembly.
Kentsis A, Gordon RE, Borden KL. Proc Natl Acad Sci U S A. (2002) 99(24):15404-15409

Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner.
Topisirovic I, Capili AD, Borden KL. Mol Cell Biol. (2002) 22(17):6183-6198

The emerging roles of translation factor eIF4E in the nucleus.
Strudwick S, Borden KL. Differentiation. (2002) 70(1):10-22

2001

The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.
Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL. J Mol Biol. (2001) 312(4):609-623

PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.
Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. EMBO J. (2001) 20(16):4547-4559